SEC Tracker
Get the app

Damora Therapeutics DMRA

OrbiMed Genesis Master Fund (Shareholder) plans to sell 9,800 DMRA shares, about $24,990

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Jul 13, 2023
  2. Broker: Bank of America
  3. Shares acquired by: Private placement

All of OrbiMed Genesis Master Fund's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 9,800 shares at $2.4 on Jul 13, 2023 ยท Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Damora Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Synlogic SYBX public float $4M, Jun 30, 2025
  2. Matinas BioPharma Holdings MTNB public float $5M, Jun 30, 2025
  3. China Pharma Holdings CPHI public float $4M, Jun 30, 2025
  4. Soligenix SNGX public float $5M, Jun 30, 2025
  5. Target Group CBDY public float $5M, Jun 30, 2025